Cochlear stock: FY27 guidance reaffirmed at Capital Markets Day

Cochlear reaffirmed its FY27 outlook on Friday, November 13, 2026, retaining a forecast for low single-digit constant-currency sales growth and underlying net profit of A$330 million to A$350 million. The company made the announcement in its Cochlear ASX announcement covering its Capital Markets Day.

Management said trading through the end of October was in line with expectations. Cochlear implant volumes in developed markets grew at a mid-single-digit rate during the period, while revenue in those markets is expected to grow modestly in FY27.

Adult implants remain the growth focus

Cochlear said adult implants in developed markets remain its main long-term value driver. The company is targeting clearer referral pathways, direct-to-consumer activity and stronger engagement with medical professionals to expand access to treatment.

Management also outlined an ambition for underlying net profit growth of around 10% per year. The presentation described that figure, together with an approximately 70% dividend payout and an A$200 million net cash target, as financial ambitions rather than annual guidance.

North America leadership transition

Lisa Aubert, Cochlear's President, North America, will leave later this year after 32 years with the company. Cochlear has started a search for her successor and said it will announce an appointment in due course.

Cochlear stock traded at 93.08 euros on Lang & Schwarz at 20:49 CET on Friday, November 13, 2026.

The Australian market backdrop is covered in the S&P/ASX 200 market overview.

More news and analyses on Cochlear stock.